DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel

First Posted Date: 2004-03-04

Last Posted Date: 2017-07-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00005096

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Valdecoxib in Treating Chronic Pain in Cancer Patients

Not Applicable

Completed

Conditions: Pain
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-02-27

Last Posted Date: 2013-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00021996

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain

Phase 2

Completed

Conditions: Pain
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-02-27

Last Posted Date: 2013-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00020618

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: rV-DF3/MUC1

First Posted Date: 2003-12-10

Last Posted Date: 2017-02-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00003761

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Gastrointestinal Stromal Tumor
Sarcoma

First Posted Date: 2003-10-07

Last Posted Date: 2010-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00069940

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Device: Hyperthermia
Radiation: XRT

First Posted Date: 2003-07-11

Last Posted Date: 2017-04-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00003045

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Rosiglitazone in Treating Patients With Liposarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: rosiglitazone maleate

First Posted Date: 2003-05-09

Last Posted Date: 2023-06-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00004180

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

Phase 2

Completed

Conditions: Liver Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2013-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00058487

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

Phase 3

Completed

Conditions: Graft Versus Host Disease

Interventions: Biological: Daclizumab
Drug: methylprednisolone
Drug: Placebo

First Posted Date: 2003-02-06

Last Posted Date: 2017-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 105

Registration Number: NCT00053976

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

and more 5 locations

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Celecoxib

First Posted Date: 2003-01-27

Last Posted Date: 2018-03-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00052611

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy